Skip to main content
. 2023 Mar 3;15(3):831. doi: 10.3390/pharmaceutics15030831

Figure 3.

Figure 3

The in vivo efficacies of resveratrol, Res-SLNs, and TPGS-Res-SLNs on mice bearing SKBR3/PR xenografts. (A) Representative images of mice on the 16th day in the different treatment groups. (B) Digital images of tumors excised from representative mice after the indicated treatments. (C) Body weight vs. time curves for mice treated with the indicated formulations. (D) Tumor weight of mice in the different treatment groups. (E) Tumor volume vs. time curves for mice treated with the indicated formulations. The data represented mean ± SD (n = 4). * p < 0.05, ** p < 0.01. Reprinted with permission of Frontiers Media S.A. under Creative Commons Attribution License (CC BY 4.0) from [71].